Repligen Reports Second Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance
– Reports second quarter revenues of $159.2 million as reported, and base business revenues of $157.1 million, down 9% year-over-year – Adjusts full year revenue guidance to range of $635-$665 million WALTHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) and first half (H1) of 2023, covering the three- and six-month fiscal periods ended June 30, 2023. Provided in this press release are financial performance highlights, updates to our guidance for the year 2023 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer of Repligen said, “2023 continues to be a challenging year for bioprocessing. Our base business performance in the second quarter and first half of 2023 held up reasonably well with base revenues down 9% and 3% respectively. Our Analytics, Proteins
